Recent Updates
Recently added Catalysts

FPyQCP

Phase 1

Colorectal Cancer | Small molecule | Oncology |Medpace Holdings, Inc. Common Stock|Last Updated: Jun 23, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment71

FDA Designations

No designations recorded

Clinical trial landscape

FPyQCP · 1 trial · 5 indications

Phase 1 1
NCT07432633[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology IndicationsColorectal Cancer
RECRUITING71 Analytics
PHASE1RECRUITING
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Colorectal Cancer
NCT0743263371
Unlock trial analytics

Study Endpoints

Primary Endpoints

Assess radiation dosimetry of [18F]FPyQCP (Cohort A)
Up to 360 minutes post injection

Whole body effective dose of a single dose of \[18F\]FPyQCP

Assess the diagnostic performance of [18F]FPyQCP in the peritoneum (Cohort B)
Until completion of follow-up procedures, up to 42 days post injection

Sensitivity and specificity of \[18F\]FPyQCP PET/CT compared to composite standard of truth

Secondary Endpoints

Incidence and severity of adverse events using CTCAE version 5.0 (Both Cohorts)
From screening until safety follow-up (48 hours post injection)
Further assess the diagnostic performance of [18F]FPyQCP (Cohort B).
Until completion of follow-up procedures, up to 42 days post injection
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeDIAGNOSTIC

Treatment Arms

ArmTypeDescription
[18F]FPyQCP PET/CTEXPERIMENTALEach participant will receive \[18F\]FPyQCP followed by positron emission tomography (PET)/computed tomography (CT) imaging at the PET/CT imaging visit (Visit 2)

Interventions

NameTypeDescription
[18F]FPyQCPDRUGpositron emission tomography (PET)/computed tomography (CT) imaging
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 80 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: 1. Participants provide informed consent and confirm that they are able and willing to comply with all protocol requirements. 2. Participants must be ≥ 18 years and \< 80 years of age and competent to give informed consent. 3. Eastern Cooperative Oncology Group performance statu...

Countries:United States
Unlock Eligibility Criteria

Competitive Landscape -Colorectal Cancer 257 trials

Top 20 of 71 competitors

CompanyTickerTrialsLead PhaseDrugs
AbbVie, Inc.ABBV8PHASE3Telisotuzumab Adizutecan, ABBV-400, Azirkitug, Budigalimab
Bristol-Myers Squibb CompanyBMY7PHASE3Ipilimumab, Nivolumab, Adagrasib, Pumitamig, BMS-986340
Merck & Co., Inc.MRK6PHASE3Pembrolizumab, Calderasib, MK-4830, Sacituzumab tirumotecan
Johnson & JohnsonJNJ5PHASE3Amivantamab, JNJ-89402638, JNJ-95437446
Pfizer Inc.PFE10PHASE3PF-08634404, Bevacizumab, Tucatinib, Trastuzumab, tisotumab vedotin
GSK plc Sponsored ADRGSK6PHASE3Dostarlimab, GSK4418959, GSK5460025
Summit Therapeutics IncSMMT3PHASE3Ivonescimab
Exelixis, Inc.EXEL5PHASE3Zanzalintinib, Cabozantinib
Agenus Inc.AGEN4PHASE3Balstilimab, Botensilimab, AGEN2034
Incyte CorporationINCY2PHASE3INCA33890, Ruxolitinib
Amgen Inc.AMGN1PHASE3Sotorasib, Panitumumab, Bevacizumab-awwb
Eli Lilly and CompanyLLY8PHASE2LY2157299, LY4066434, Cetuximab, Gemcitabine, Pemetrexed
AstraZeneca PLCAZN8PHASE2Datopotamab deruxtecan, Volrustomig, Rilvegostomig, FPI-2053, FPI-2107
Takeda Pharmaceutical Co. Ltd. Sponsored ADRTAK5PHASE2fruquintinib
BioNTech SE Sponsored ADRBNTX3PHASE2Autogene cevumeran, Pumitamig, BNT314
Novartis AG Sponsored ADRNVS7PHASE2Dabrafenib, trametinib, Opnurasib, TNO155, DKY709
Regeneron Pharmaceuticals, Inc.REGN2PHASE2Cemiplimab
Revolution Medicines, Inc.RVMD7PHASE1Elironrasib, Daraxonrasib, Zoldonrasib, RMC-5127
Jazz Pharmaceuticals Public Limited CompanyJAZZ2PHASE2Zanidatamab
Cardiff Oncology, Inc.CRDF1PHASE2Onvansertib
Unlock Competitive Intelligence

Explore more on BiopharmaWatch

Medpace Holdings, Inc. Common Stock (MEDP)Pipeline, catalysts, financials, insiders and newsColorectal Cancer disease mapEvery company developing for Colorectal Cancer, by stage and capitalFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with FCompanies A to ZEvery biotech and pharma company we track